Richard Adcock, ImmunityBio CEO

Im­mu­ni­ty­Bio inks roy­al­ty deal, pri­vate place­ment to raise $210M for blad­der can­cer drug com­bo

Im­mu­ni­ty­Bio has struck a roy­al­ty deal and a pri­vate place­ment to raise up to $320 mil­lion as it eyes a po­ten­tial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.